📊 CTSO Key Takeaways
Is Cytosorbents Corp (CTSO) a Good Investment?
Cytosorbents exhibits a financially distressed profile with unsustainable losses (-$5.1M net income, -$1.2M operating cash flow) despite a strong 69.2% gross margin, indicating the core product has merit but operations are severely inefficient. Dangerously high leverage (7.73x Debt/Equity) combined with tight liquidity (1.09x current ratio, 0.81x quick ratio) and minimal equity cushion ($2.2M) create substantial refinancing and solvency risk, far outweighing modest revenue growth of 4.1%.
Cytosorbents shows decent top-line growth and strong gross margins, but the business remains structurally unprofitable at the operating level and is consuming cash. The balance sheet still supports near-term operations, yet elevated leverage, negative free cash flow, and thin equity make the growth profile lower quality until operating losses narrow materially.
Cytosorbents Corp Key Strengths (CTSO)
- Strong gross margin of 69.2% demonstrates viable product and pricing power
- Revenue growing 4.1% YoY with positive market traction in medical devices
- Net losses improving 65.8% YoY from -$0.22 to -$0.08 per share, showing trend toward breakeven
- Revenue grew 14.5% year over year, indicating continued commercial demand
- Gross margin of 70.7% suggests attractive product-level economics
- Current ratio of 2.11x and quick ratio of 1.71x provide reasonable near-term liquidity
CTSO Stock Risks: Cytosorbents Corp Investment Risks
- Severe operating losses (-$3.0M) and negative free cash flow (-$1.2M) with no clear path to profitability
- Dangerously high leverage at 7.73x Debt/Equity with $17.0M long-term debt against $2.2M equity base
- Tight liquidity and solvency risk: current ratio 1.09x, quick ratio 0.81x, and minimal equity buffer for adverse events
- Operating expenses far exceed gross profit, indicating severe scaling inefficiency relative to revenue base
- Operating margin of -37.2% shows the company is still far from sustainable profitability
- Free cash flow of -7.61M and negative operating cash flow indicate ongoing cash burn
- Debt-to-equity of 1.61x with only 9.02M of equity leaves limited balance-sheet flexibility
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Operating expense reduction and gross profit leverage into profitability
- Debt refinancing risk and covenant compliance with current leverage levels
- Operating cash flow and free cash flow trend
- Operating margin improvement versus revenue growth
Cytosorbents Corp (CTSO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Cytosorbents Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CTSO Profit Margin, ROE & Profitability Analysis
CTSO vs Healthcare Sector: How Cytosorbents Corp Compares
How Cytosorbents Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cytosorbents Corp Stock Overvalued? CTSO Valuation Analysis 2026
Based on fundamental analysis, Cytosorbents Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cytosorbents Corp Balance Sheet: CTSO Debt, Cash & Liquidity
CTSO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cytosorbents Corp's revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $-0.38 indicates the company is currently unprofitable.
CTSO Revenue Growth, EPS Growth & YoY Performance
CTSO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.7M | -$1.5M | $-0.02 |
| Q3 2025 | $8.6M | -$2.7M | $-0.04 |
| Q2 2025 | $8.8M | $469.0K | $0.01 |
| Q1 2025 | $8.7M | -$1.5M | $-0.02 |
| Q3 2024 | $8.8M | -$2.3M | $-0.04 |
| Q2 2024 | $9.4M | -$4.1M | $-0.08 |
| Q1 2024 | $9.4M | -$6.4M | $-0.12 |
| Q3 2023 | $8.1M | -$9.2M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cytosorbents Corp Dividends, Buybacks & Capital Allocation
CTSO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cytosorbents Corp (CIK: 0001175151)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTSO
What is the AI rating for CTSO?
Cytosorbents Corp (CTSO) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTSO's key strengths?
Claude: Strong gross margin of 69.2% demonstrates viable product and pricing power. Revenue growing 4.1% YoY with positive market traction in medical devices. ChatGPT: Revenue grew 14.5% year over year, indicating continued commercial demand. Gross margin of 70.7% suggests attractive product-level economics.
What are the risks of investing in CTSO?
Claude: Severe operating losses (-$3.0M) and negative free cash flow (-$1.2M) with no clear path to profitability. Dangerously high leverage at 7.73x Debt/Equity with $17.0M long-term debt against $2.2M equity base. ChatGPT: Operating margin of -37.2% shows the company is still far from sustainable profitability. Free cash flow of -7.61M and negative operating cash flow indicate ongoing cash burn.
What is CTSO's revenue and growth?
Cytosorbents Corp reported revenue of $8.9M.
Does CTSO pay dividends?
Cytosorbents Corp does not currently pay dividends.
Where can I find CTSO SEC filings?
Official SEC filings for Cytosorbents Corp (CIK: 0001175151) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTSO's EPS?
Cytosorbents Corp has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CTSO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cytosorbents Corp has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CTSO stock overvalued or undervalued?
Valuation metrics for CTSO: ROE of -233.8% (sector avg: 15%), net margin of -57.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CTSO's AI grade for 2026?
Our dual AI analysis gives Cytosorbents Corp a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTSO's free cash flow?
Cytosorbents Corp's operating cash flow is $-1.2M, with capital expenditures of $11.0K. FCF margin is -13.2%.
How does CTSO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -57.9% (avg: 12%), ROE -233.8% (avg: 15%), current ratio 1.09 (avg: 2).
Is Cytosorbents Corp carrying too much debt?
CTSO has a debt-to-equity ratio of 7.73x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.09 suggests adequate short-term liquidity.